Target therapies in systemic lupus erythematosus: Current state of the art

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 10, 2010, Pages 956-965

  Wiesik Szewczyk, E ^a   Lacki, J K ^a   Feleszko, W ^b   Olesinska, M ^a  

^a INSTITUTE OF RHEUMATOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Anti cytokine therapy; B cells; BLyS; Clinical trials; Epratuzumab; LJP 394; Monoclonal antibodies; Rituximab; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; ABETIMUS; ACETYLSALICYLIC ACID; ATACICEPT; BELIMUMAB; BG 9588; CD40 LIGAND; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DIPHENHYDRAMINE; EDRATIDE; EPRATUZUMAB; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 6; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY IDEC 131; OCRELIZUMAB; PARACETAMOL; PREDNISONE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERATIDE;

ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BIOLOGICAL ACTIVITY; CELL INTERACTION; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HELPER CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MOLECULARLY TARGETED THERAPY; NEPHRITIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT MONITORING; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD20; ANTIGENS, CD22; CD40 LIGAND; HUMANS; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; ORGANIC CHEMICALS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956674216     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955710792007187     Document Type: Article

References (72)

1. Bernatsky, S.; Boivin, J-F.; Joseph, L.; Manzi, S.; Ginzler, E.; Gladman, D.D.; Urovitz, M.; Fortin, P.R.; Petri, M.; Barr, S.; Gordon, C.; Bae, S.-C.; Isenberg, D.; Zoma, A.; Aranow, C.; Doo-ley, M.-A.; Nived, O.; Sturfelt, G.; Steinsson, K.; Alarcon, G.; Senegal, J.-L.; Zummer, M.; Hanly, J.; Ensworth, S.; Pope, J.; Ed-wirthy, S.; Rahamn, A.; Sibley, J.; El-Gabalawy, H.; McCarthy, T.; Pierze, Y.S.T.; Clarke, A.; Ramsey-Goldman, R. Mortality in sys-temic lupus erythematosus. Arthritis Rheum., 2006, 54, 2250-2257.
2. Bernatsky, S.; Joseph, L.; Boivne, J-F.; Gordon, C.; Urovitz, M.; Gladman, D.; Fortin, P.R.; Ginzler, E.; Bae, S-C.; Barr, S.; Edwor-thy, S.; Isenberg, D.; Rahman, A.; Petri, M.; Alarcon, G.S.; Ara-now, C.; Dooley, M-A.; Rajan, R.; Senegal, J-L.; Zummer, M.; Manzi, S.; Ramsey-Goldman, R.; Clarke, A.E. The relationship be-tween cancer and medication exposures in systemic lupus erythe-matosus: a case cohort study. Ann. Rheum. Dis., 2008, 67, 74-79.
3. Boumpas, D.T.; Austin, H.A.; Vaughan, E.M.; Yaboro, C.H.; Klip-pel, J.H.; Balow, J.E. Risk for susteined amenorrhea in patientswith systemic lupus erythematosus receiving intermittent pulse cy-clophosphamide. Ann. Intern. Med., 1993, 119, 366-369.
4. Lacki, J.K. Management of the patient with severe refractoryrheumathoid arthritis: are the newer treatment options worth con-sidering? BioDrugs, 2000, 13, 425-435.
5. Olesinska, M.; Chwalinska-Sadowska, H.; Mielnik, P.; Wiesik-Szewczyk, E. Biological therapies of systemic lupus erythemato-sus. Pol. Merkur. Lekarski, 2006, 20, 371-373.
6. Anolik, J.H. B cell biology and dysfunction in SLE. Bull NYUHosp Jt Dis., 2007, 65,182-186.
7. Jacobi, A.M.; Diamond, B. Balancing diversity and tolerance:lessons from patients with systemic lupus erythematosus. J. Exp.Med., 2005, 202, 341-344.
8. Silverman, J.G.; Wiesman, S. Rituximab therapy and autoimmunedisorders. Prospects for anti-B cell therapy. Arthritis Rheum., 2003,6, 1484-1492.
9. Anolik, J.H.; Bernard, J.; Cappione, A.; Puch-Bernard, A.E.; Felga, R.E.; Looney, R.J.; Sanz, I. Ritiximab improves peripheral B cellabnormalities in human systemic lupus erythematosus. ArthritisRheum., 2004, 11, 3580-3590.
10. Anolik, J.H.; Bernard, J.; Owen, T.; Zheng, B.; Kemshetti, S.; Looney, R.J.; Sanz, I. Delayed memory B cell recovery in periph-eral blood and lymphoid tissue in systemic lupus erythematosus af-ter B cell depletion therapy. Arthritis Rheum., 2007, 56, 3044-3056.
11. Perrotta, S.; Locatelli, F.; La Manna, A.; Cennamo, L.; De Stefano, P.; Nobili, B. Anti-CD20 monoclonal antibody (Rituximab) forlife-threatening autoimmune haemolytic anaemia in patient withsystemic lupus erythematosus. Br. J. Haematol., 2002, 116, 465-467.
12. Looney, R.J.; Anolik, J.H.; Campbell, D.; Felga, R.E.; Young, F.; Arend, L.J.; Sloand, J.A.; Rosenblatt, J.; Sanz, I. B. cell depletion asa novel treatment for systemic lupus erythematosus. A phase I/IIdose-escalation trial of rituximab. Arthritis Rheum., 2004, 50,2580-2589.
13. Leandro, M.J.; Edwards, J.C.; Cambridge G., Ehreinstein, M.R.; Insenberg, D.A. An open study of B lymphocyte depletion in sys-temic lupus erythematosus. Athritis Rheum., 2002; 46: 2673-2677.
14. Leandro, M.J.; Cambrige, G.; Edwards, J.C.; Ehrenstein, M.R.; Isenberg, D.A. B-cell depletion in treatment of patients with sys-temic lupus erythematosus: a longitudinal analysis of 24 patients.Rheumatology, 2005, 44, 1542-1545.
15. Tahir, H.; Rohrer, J.; Bhatia, A.; Wegener, W.A.; Isenberg, D.A. Humanized anti CD-20 monoclonal antibody in the treatment ofsevere resistant systemic lupus erythematosus in patient with anti-bodies against rituximab. Rheumatology, 2005, 44, 561-562.
16. Smith, K.G.C.; Jones, R.B.; Burns, S.M.; Jayne, D.R.W. Long-termcomparison of rituximab treatment for refractory systemic lupuserythematosus and vasculitis. Remission, relapse, re-treatment. Ar-thritis Rheum., 2007, 54, 2970-2982.
17. Sfikakis, P.P.; Boletis, J.N.; Lionaki, S.; Vigklis, V.; Fragiadaki, K.G.; Iniotaki, A.; Moutsopoullos, H.M. Remission of proliferativelupus nephritis following B cell depletion therapy is preceded bydown-regulation of the T cell costimulatory molecule CD40 ligand.An open-label trial. Arthritis Rheum., 2005, 52, 501-513.
18. Gunnarson, I.; Sundelin, B.; Jónsdotir, T.; Jacobson, S.H.; Henriks-son, E.W.; von Vollenhoven, R.F. Histhopathologic and clinicaloutcome of rituximab treatment in patients with cyclophos-phamide-resistant proliferative lupus nephritis. Arthritis Rheum.,2007, 56, 1263-1272.
19. Tanaka, Y.; Yamamoto, K.; Takeuchi, T.; Nishimoto, N.; Mi-yasaka, N.; Sumida, T.; Shima, Y.; Takada, K.; Matsumoto, I.; Saito, K.; Koike, T. A multicenter phase I/II trial of rituximab forrefractory systemic lupus erythematosus. Mod Rheumatol., 2007,17, 191-197.
20. Jonsdottiur, T.; Gunnarson, I.; Risseada, A.; Nenriksson, E.W.; Klareskog, L.; Vollehowen, R.F. Treatment of refractory SLE withrituximab plus cyclophosphamide: clinical effects serologicalchanges and predictors of response. Ann. Rheum. Dis., 2008, 67,330-334.
21. Lindholm, C.; Börjesson-Asp, K.; Zendjanchi, K.; Sundqvist, A-C.; Tarkowski, A.; Bokarewa, M. Longterm clinical and immunologi-cal effects of anti-CD20 treatment in patients with refractory sys-temic lupus erythematosus. J. Rheumatol., 2008, 35, 826-833.
22. Anolik, J.H.; Campbell, D.; Felgar, F.; Young, F.; Sanz, I.; Rosen-blatt, J.; Looney, R.J. The relationship of FcgammaRIIIa genotypeto degree of B cell depletion by rituximab in the treatment of sys-temic lupus erythematosus. Arthritis Rheum., 2003, 48, 455-459.
23. Furst, D.E.; Breedveld, F.C.; Kalden, J.R.; Smolen, S.J.; Burmester, G.R.; Sieper, J.; Emery, P.; Keystone, E.C.; Schiff, M.H.; Mease, P.; van Riel P.L.C.M.; Fleischmann, R.; Weissman M.H.; Weinblatt, M.E. Updated consensus statement on biologicalagents for the treatment of rheumatic diseases. Ann. Rheum. Dis.,2007, 66, iii2-iii22.
24. FDA. Information for healthcare professionals: Rituximab (mar-keted as Rituxan). http:/www.fda.gov/cder/drug/infopage/rituxi-mab/default.htm.
25. Boren, E.J.; Cheema, G.S.; Naguwa, S.M.; Ansari, A.A.; Gershwin, M.E. The emergence of progressive multifocal leucoen-cephalopathy (PML) in rheumatic diseases. Rev. J. Autoimmun.,2008, 30, 90-98.
26. Gottenberg, J.E. Guillevin, L.; Lambotte, O.; Combe, B.; Allanore, Y.; Cantagrel, A.; Larroche, C.; Subrier, M.; Bouillet, L.; Dou-gados, M.; Fain, O.; Farge, D.; Kyndt, X.; Lortholary, O.; Mason, C; Moura, B.; Remy, P.; Thomas, T.; Wendling, D.; Anaya, J.M.; Sibilia, J.; Mariette X. Tolerance and short-term efficacy of rituxi-mab in 43 patients with systemic autoimmune diseases. Ann.Rheum. Dis., 2005, 64, 913-920.
27. Merill, J.T.; Neuwelt, C.M.; Wallace, D.J.; Shanahan, J.C.; Latinis, K.M.; Oates, J.C.; Utset, T.O.; Gordon, C.; Isenberg, D.A.; Hsieh, H-J.; Zhang, D.; Brunetta, P.G. Efficacy and safety of rituximab inmoderately to severely active systemic lupus eythematosus. Therandomized double-blind, phase II/III systemic lupus eythematosusevaluation of rituximab trial. Arthritis Rheum., 2010, 62, 222-233.
28. Isenberg, D.; Gordon, C.; Merrill, J.; Urovitz, M. New therapies insystemic lupus erythematosus trials, troubles and tribulations...working towards a solution. Lupus, 2008, 17, 967-970.
29. Tender, T.F.; Tuscano, J.; Sato, S.; Kehrl, J.H. CD22, a lympho-cyte-specific adhesion molecule that regulates antigen receptor sig-naling. Annu. Rev. Immunol., 1997, 15, 481-504.
30. Peaker, C.J.; Neuberger, M.S. Association of CD22 with the B cellantigen receptor. Eur. J. Immunol., 1993, 23, 1358-1363.
31. Nato, D., van der Merwe, P.A.; Kelm, S.; Bradfield, P., Cocker, P.R. The amino-terminal immunoglobulin-like domain of siaload-hesin contains the sialicic acid binding site. Comparison withCD22. J. Biol. Chem., 1995, 270, 26184-26191.
32. Clarc, E.A. CD22, a B cell-specific receptor, mediates adhesionand signal transduction. J. Immunol., 1993, 15, 4715-4718.
33. Leonard, J.P.; Coleman, M.; Ketas, J.C.; Chadburn, A.; Ely, S.; Furman, R.R.; Wegener, W.A.; Hansen, H.J.; Ziccardi, H.; Eschen-berg, M.; Gayko, U.; Cesano, A.; Goldenberg, D.M. Phase I/II trialof epratuzumab (humanizes anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J. Clin. Oncol., 2003, 21, 3051-3059.
34. Leonard, J.P.; Coleman, M.; Ketas, J.C.; Chadburn, A.; Furman, R.; Schuster, M.W.; Feldman, E.J.; Asha, M.; Schuster, S.J.; Wegener, W.A.; Hansen, H.J.; Ziccardi, H.; Eschenberg, M.; Gayko, U.; Fields, S.Z.; Cesano, A.; Goldenberg, D.M. Epratuzu-mab, a humanized anti-CD22 antibody, in aggresive non-Hodgkinlymphoma: phase I/II clinical trial results. Clin. Cancer Res., 2004,15, 5327-5334.
35. Dörner, T.; Kaufmann, J.; Wegener, W.A.; Teoh, N.; Goldenberg, D.M.; Burmester, G.R. Initial clinical trial of epratuzumab (human-ized anti-CD22 antibody) for immunotherapy of systemic lupuserythematosus. Arthritis Res. Ther., 2006, 8, 1-11.
36. Jacobi, A.M.; Goldenberg, D.M.; Hiepe, F.; Radbruch, A.; Burmester, G.R.; Dörner, T. Differential effects of epratuzumab onperipheral blood B cells of patients with systemic lupus erythema-tosus versus normal controls. Ann. Rheum. Dis., 2008; 67, 450-457.
37. Petri, M.; Hobbs; K.; Gordon, C.; Strand, V.; Wallace, D.; Kelly, L.; Wegener, W.; Barry, A. Randomized controlled trials (RCTS) of epratuzumab (anty-CD22 targeting B-cells) reveal clinically meaningful improvements in patients with moderate/severe SLE flares. Ann. Rheum. Dis., 2008, 67, 53S.
38. Zhang, J.; Roschke, V.; Backer, K.P.; Wang, Z.; Alarcn, G.S.; Fessler, B.J.; Bastin, H.; Kimberly, R.P.; Zhou, T. Cutting edge: arole for B lymphocyte stimulator in systemic lupus erythematosus.J. Immunol., 2001, 166, 6-10.
39. Cheema, G.S.; Roschke, V.; Hilbert, D.M.; Stohl, W. Elevatedserum B lymphocyte stimulator levels in patients with systemicimmune-based rheumatic diseases. Arthritis Rheum., 2001, 44,1313-1319.
40. Stohl, W.; Metyas, S.; Tan, S-M.; Cheeme, G.S.; Oamar, B., Xu, D.; Roschke, V.; Wu, Y.; Baker, K.P.; Hilbert, D.M. B lymphocytestimulator (BLyS) overexpression in patients with systemic lupuserythematosus: longitudinal observations. Arthritis Rheum., 2003,48, 3475-3486.
41. Stohl, W. A therapeutic role for BLyS antagonists. Lupus, 2004,13, 317-322.
42. Baker, K.P.; Edwards, B.M.; Main, S.H.; Choi, G.H.; Wager, R.E.; Halpern, W.G.; Cappin, P.B.; Riccobene, T.; Abramian, D.; Sekut, L.; Sturm, B.; Poortman, C.; Minter, R.R.; Dobson, C.L.; Williams, E.; Carmen, S.; Smith, R.; Roschke, V.; Hilbert, D.M.; Vaughan, T.J.; Albert, V.R. Generation and characterization of Lymphostat-Ba human monoclonal antibody that agonizes BLyS bioactivities.Arthritis Rheum., 2003, 48, 3253-3265.
43. Wallace, D.J.; Stohl, W.; Furie, R.A.; Lisse, J.R.; McKay, J.D.; Merrill, J.T.; Petri, M.; Ginzler, E.M.; Chatham, W.W.; McCune, J.; Fernandez, V.; Chevrier, M.; Zhong, Z.J.; Freimuth, W. A phaseII, randomized, duble-blind, placebo-controlled, dose ranging studyof belimumab in patients with active systemic lupus erythematosus.Arthritis Rheum. (Arthritis Care Res), 2009, 61, 1168-1178.
44. Ramanujam, M.; Wang, X.; Huang, W.; Schiffer, L.; Grimaldi, C.; Akkerman, A.; Diamond, B.; Madaio, M.P.; Davidson, A. Mecha-nism of action of transmembrane activator and calcium modulatorligand interactor-Ig in murine systemic lupus erythematosus. J.Immunol., 2004, 173, 3524-3534.
45. Koyama, T.; Tsukamoto, H.; Miyagi, Y.; Himeji, D.; Otsuka, J.; Mijagawa, H. et al. Raised serum APRIL levels in patients withsystemic lupus erythematosus. Ann. Rheum. Dis., 2005, 64, 1065-1067.
46. Gross, J.A.; Dillon, S.R.; Mudri, S.; Johnston, J.; Littau, A.; Roque, R.; Rixon, M.; Schon, O.; Foley, K.P.; Hangen, H.; McMiller, S.; Waggie, K.; Schreckhise, R.W.; Shoemaker, K.; Vu, T.; Moore, M.; Grossman, A.; Clegg, C.H. TACI-IgG neutralizes moleculescritical for B cell development and autoimmune disease: impairedB cell maturation in mice lacking BLyS. Immunity, 2001, 15, 289-302.
47. Gross, J.A.; Johnston, J.; Mudri, S.; Enselman, R.; Dillon, S.; Mad-den, K.; Xu, W.; Parrish-Novak, J.; Foster, D.; Lofton-Day, C.; Moore, M.; Littan, A.; Grossman, A.; Haugen, H.; Foley, K.; Blumberg, H.; Harrisin, K.; Kindsvogel, W.; Clegg, C.H. TACI andBCMA are receptors for TNF homologue implicated in B-cell auto-immune disease. Nature, 2000, 404, 995-997.
48. Dall'Era, M.; Chacravarty, E.; Wallace, D.; Genovese, M.; Weis-man, M.; Kavanaugh, A.; Kalunian, K.; Dar, P.; Vincent, E.; Pena-Rossi, C.; Wofsy, D.; Merck Serono and ZymoGenetics AtaciceptStudy Group. Reduced B lymphocyte and immunoglobulin levelsafter atacicept treatment in patients with systemic lupus erythema-tosus. Results of multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum., 2007, 56, 4142-4150.
49. Dall'Era, M.; Davis, J. CTLA4Ig: a novel inhibitor of costimula-tion. Lupus, 2004, 13, 372-376.
50. Kremer, J.M.; Westhovens, R.; Leon, M.; Di Giorgio, E.; Alten, R.; Steinfeld, S.; Russel, A.; Dougados, M.; Emery, P.; Nuamah, I.F.; Williams, G.R.; Becker, J.C., Hagerty, D.T.; Moreland, L.W. Treatment of rheumatoid arthritis by selective inhibition of T-cellactivation with fusion protein CTLA-4Ig. N. Engl. J. Med., 2003,349, 1907-1915.
51. Genovese, M.C.; Becker, J.C.; Schiff, M.; Luggen, M.; Sherrer, Y.; Krenler, J.; Birbara, C.; Box, J.; Natarajan, K.; Nuamah, I.; Li, T.; Aranda, R.; Hagerty, D.T.; Dougados, M. Abatacept for rheuma-toid arthritis refractory to tumor necrosis factor alpha inhibition. N.Engl. J. Med., 2005, 353, 1114-1123.
52. Daikh, D.; Wofsky, D. Cutting edge: Reversal of murine lupusnephritis with CTLA-4Ig and cyclophosphamide. J. Immunol.,2001, 166, 2913-2916.
53. Yazdany, J.; Davis, J. The role of CD40 ligand in systemic lupuserythematosus. Lupus, 2004, 13, 377-380.
54. Davis, J.C.; Totoritis, M.C.; Rosenberg, J.; Sklenar, T.A.; Wofsy,D. Phase I clinical trial of monoclonal antibody against CD40-Ligand (IDEC-131) in patients with systemic lupus erythematosus.J. Rheumatol., 2001, 28, 95-101.
55. Kalunian, K.C.; Davis, J.C. Jr.; Merrill, J.T.; Totoritis, M.C.; Wofsy, D.; for the IDEC-131 Lupus Study Group. Treatment ofsystemic lupus erythematosus by inhibition of T cell costimulationwith anti-CD154. Arthritis Rheum., 2002, 46, 3252-3258.
56. Boumpas, D.T.; Furie, R.; Manzi, S.; Illei, G.G.; Wallace, D.J.; Balow, J.E.; Vaishnaw, A. BG9598 Lupus Nephritis Trial Group.A short course of BG9588 (anti-CD-40L antibody) improves sero-logic activity and decreases hematuria in patients with proliferativelupus gromerulonephritis. Arthritis Rheum., 2003, 48, 719-727.
57. Henn, V.; Slupsky, J.R.; Grafe, M.; Anagnostopoulos, J.; Förster, R.; Müler-Berghaus, G.; Kroczek, S.A. CD40 ligand on activatedplatelets triggers an inflammatory reaction of endothelial cells. Na-ture, 1998, 391, 591-594.
58. Linnik, M.D.; Hu, J.Z.; Heilbrunn, K.R.; Strand, V.; Hurley, F.L.; Joh, T.; LJP 394 Invastigator Consortium. Relationship betweendouble-stranded DNA antibodies and exacerbation of renal diseasein patients with systemic lupus erythematosus. Arthritis Rheum.,2005, 52, 1129-1137.
59. Wallece, D.J.; Tumlin, J.A. LJP 394 (abetimus sodium, Riquent) inthe management of systemic lupus erythematosus. Lupus, 2004, 13,323-327.
60. Alarc n-Segovia, D.; Tumlin, J.A.; Furie, R.A.; McKay, J.D.; Cardiel, M.H.; Strand, V.; Bagin, R.G.; Linnik, M.D.; Hepburn, B.;LJP 394 Investigator Consortium. LJP 394 for the prevention of re-nal flare in patients with systemic lupus erythematosus. Resultsfrom a randomized, double-blind, placebo controlled study. Arthri-tis Rheum., 2003, 48, 442-454.
61. Lacki, J.K.; Leszczynski, P.; Kelemen, J.; Muller, W.; Mackiewicz,S.H. Cytokine concentration in serum of lupus erythematosus pa-tients: the effect on acute phase response. J. Med., 1997, 28, 99-107.
62. De Brandt, M.; Sibilia, J.; Le Loet, X.; Prouzean, S.; Fautrel, B.; Marcelli, C.; Boucguillard, E.; Siame, J.L.; Mariette, X.; ClubRheumatismes et Inflammation. Systemic lupus erythematosus in-duced by anti-tumor necrosis factor alpha therapy: a French na-tional survey. Arthritis Res. Ther., 2005, 7, R545-51.
63. Mohan, A.K.; Edwards, E.T.; Cote, T.R.; Siegel, J.N.; Braun, M.M.Drug-induced systemic lupus erythematosus and TNF-alpha block-ers. Lancet, 2002, 360, 646.
64. Aringer, M.; Smolen, J.S. Tumor necrosis factor and other proin-flammatory cytokines in systemic lupus erythematosus: rational fortherapeutic intervention. Lupus, 2004, 13, 344-347.
65. Segal, S.; Bermas, B.; Dayan, M.; Kaluah, F.; Shearer, G.M.; ozes, E. Kinetics of cytokine production in experimental sys-temic lupus erythematosus: involvement of T helper cell/T helpercell 2-type cytokines in disease. J. Immunol., 1997, 158, 3009-3016.
66. Aringer, M.; Graninger, W.B.; Steiner, G.; Smolen, J.S. Safety andefficacy of tumor necrosis factor alpha blockade in systemic lupuserythematosus. An open-label study. Arthritis Rheum., 2004, 50,3161-3169.
67. Tackey, Y.; Lipsky, P.E.; Illei, G.G. Rationale for interleukin-6blockade in systemic lupus erythematosus. Lupus, 2004, 13, 339-343.
68. Lacki, J.K.; Samborski, W.; Mackiewicz, S.H. Interleukin-10 andinterleukin-6 in lupus erythematosus and rheumatoid arthritis, cor-relations with acute phase proteins. Clin. Rheumatol., 1997, 16,275-278.
69. Liang, B.; Gardner, D.B.; Griswold, D.E.; Bugelski, P.J.; SongXiao, Y.R: Anti-interleukin-6 monoclonal antibody inhibits auto-immune responses in a murine model of systemic lupus erythema-tosus. Immunology, 2006, 119, 296-305.
70. Schattner, A.; Liang, M.H. The cardiovascular burden of lupus: acomplex challenge. Arch. Intern. Med., 2003, 163, 1507-1510.
71. Suntharalingam, G.; Perry, M.R.; Ward, S.; Brutt, S.J.; Castello-Cortes, A.; Brunner, M.D.; Panoskaltsis, N. Cytokine storm inphase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N.Engl. J. Med., 2006, 355, 1018-1028.
72. Furie, R.A.; Petri, M.; Wallace, D.J.; Ginzler, E.M.; Merril, J.T.; tohl, W.; Chatham, W.W.; Strand, V.; Weinstein, A.; Chevier, R.; Zhong, J.Z.; Freimuth, W.W. Novel evidence -based sys-temic lupus erythematosus responder index. Arthritis Rheum. (Ar-thritis Care Res), 2009, 61, 1143-1151.